SNDX Stock Analysis: Buy, Sell, or Hold?
SNDX - Syndax Pharmaceuticals, Inc.
$21.82
0.93 (4.45%)
▲
5d:
+10.15%
30d:
+18.65%
90d:
-8.63%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 03, 2026
30d
Smart Money Accumulation
None View Scanner →
Strength: 7.0/10
Get Alerted When SNDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SNDX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SNDX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SNDX is currently trading at $21.82, which is considered extended relative to its 30-day fair value range of $17.88 to $20.61. From a valuation perspective, the stock is trading at a discount (Forward PE: -41.7) compared to its historical average (126.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SNDX is in a strong uptrend. The price is approaching resistance at $22.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: SNDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.00 (+78.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SNDX is in a strong uptrend. The price is approaching resistance at $22.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: SNDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.00 (+78.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.88 -
$20.61
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+5.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.5%)
- BULLISH: Trading 78.7% below Wall St target ($39.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$17.88 -
$20.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.93
Resistance Level
$22.34
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-41.71
Wall Street Target
$39.00
(+78.7%)
Revenue Growth (YoY)
223.6%
Profit Margin
-112.0%
PE vs Historical
-41.7 vs 126.3
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Keith A Goldan
SELL
3410 shares
2026-02-09
Michael A Metzger
SELL
17159 shares
2026-02-09
Keith A Goldan
SELL
2082 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
Advanced SNDX Option Strategies
Professional options setups generated by AI based on today's SNDX price and gamma walls.
